A review of current data to support decision making for introduction of next generation higher valency pneumococcal conjugate vaccination of immunocompetent older adults in the UK.

Vyse, Andrew; Campling, James; Czudek, Carole; Ellsbury, Gillian; Mendes, Diana; Reinert, Ralf-Rene; Slack, Mary

Vyse, Andrew; Campling, James; Czudek, Carole; Ellsbury, Gillian; Mendes, Diana; Reinert, Ralf-Rene; Slack, Mary.

Affiliation

Vyse A; Medical Affairs, Pfizer Ltd, Walton Oaks, Tadworth, KT20 7NS, UK.
Campling J; Medical Affairs, Pfizer Ltd, Walton Oaks, Tadworth, KT20 7NS, UK.
Czudek C; Medical Affairs, Pfizer Ltd, Walton Oaks, Tadworth, KT20 7NS, UK.
Ellsbury G; Medical Affairs, Pfizer Ltd, Walton Oaks, Tadworth, KT20 7NS, UK.
Mendes D; Health & Value, Pfizer Ltd, Walton Oaks, Tadworth, KT20 7NS, UK.
Reinert RR; Medical Affairs, Pfizer Inc, Paris, France.
Slack M; School of Medicine & Dentistry, Griffith University, Gold Coast Campus, Queensland 4222, Australia.

Expert Rev Vaccines ; 20(10): 1311-1325, 2021 Oct.

Article in En | MEDLINE | ID: mdl-34550850

Subject(s)
Key words

Adult; community acquired pneumonia; cost effectiveness; epidemiology; invasive pneumococcal disease; pneumococcal conjugate vaccines

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pneumococcal Infections / Pneumococcal Vaccines Type of study: Clinical_trials / Observational_studies Limits: Aged / Humans Country/Region as subject: Europa Language: En Journal: Expert Rev Vaccines Journal subject: ALERGIA E IMUNOLOGIA Year: 2021 Document type: Article Affiliation country: Reino Unido

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google